Nvidia Plants Its Flag in Drug Discovery
The day's biggest theme is a chipmaker muscling deeper into medicine. Nvidia is deepening its bets on AI-driven drug discovery with an investment in Recursion, according to Reuters — a sign the company sees finding new medicines as a core market, not a side project. Reinforcing that push, Nvidia has launched a toolkit called BioNeMo aimed at the life sciences industry, and Yahoo Finance reports companies in the field are racing to adopt it. Between hardware, investment, and software, Nvidia is positioning itself as foundational infrastructure for the next generation of AI biology.
From Pitch Deck to Clinic — Slowly
For years, AI-designed medicines lived mostly in pitch decks and press releases. Tech Times (via Bing News) reports that began to change in 2025, when AI drug discovery cleared its first real clinical test — an early but meaningful milestone for a field long heavy on promise. The caveat comes from the bench: Clinical Lab Products notes that while AI is moving deeper into pharmaceutical and life science research, a closer look shows the technology is still finding its footing in the lab. Read together, the message is momentum tempered by reality.
Oncology Is Where the Money Moves
Cancer dominated the deal flow. Boehringer Ingelheim struck a $15 million discovery collaboration with Immunai, an Israeli-founded AI biotech, to hunt for cancer drug targets, per the partnership terms. Elsewhere, News-Medical reports AI is being used to better forecast drug resistance — the frustrating point at which a treatment that once worked stops holding a tumor back — potentially sharpening the odds for patients and clinicians alike.
Regulators and Lobbyists Sharpen Their Pens
Two drugmakers spent the week answering hard questions. Endpoints News reports the European Commission has opened an investigation into Sanofi's sales practices, while Akeso defends one of its cancer drugs under scrutiny. On the policy front, geneonline.com reports BIO chief executive John F. Crowley is pushing a single playbook that ties AI, regulation, and national security together rather than treating them as separate silos — an argument that the industry's future is one interlocking question.
Science at the Frontier
Beyond the deals, researchers reported striking advances. Ars Technica describes an antibiotic "megacluster" that points to a fresh strategy against drug-resistant superbugs. The Scientist reports machine learning could push genetic code expansion closer to commercial biotech reality. Nature suggests AI may reshape how doctors study and treat disorders of consciousness, among medicine's hardest conditions. And Insilico, an AI-pharma pioneer, laid out a two-part ambition: become China's No. 1 drugmaker and build a "God-like" longevity drug. Lofty — but emblematic of a day when AI's reach in pharma stretched from the clinic to the very limits of the lifespan.